FDA Compounding Status and Peptide Safety Update

Clinical Question

What is the current regulatory standing and safety profile of frequently compounded peptides according to FDA status, warning letters, and post-marketing surveillance data?

Evidence Snapshot

• Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently listed as FDA Category 2 bulk substances, rendering them ineligible for routine compounding due to safety risks.
• Warning Letters: Regulatory actions have been issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (2020) regarding various peptide products.
• Clinical Trials (Phase III): Semaglutide (STEP 1, SELECT) and Tirzepatide (SURMOUNT-1, SURMOUNT-5) have completed pivotal trials. Thymosin Alpha-1 (NCT02867267) demonstrated negative results for mortality reduction in sepsis.
• Safety Signals: Emerging signals for Semaglutide include NAION (96 cases), intestinal obstruction, and pulmonary aspiration, while compounding concerns for TB-500 and BPC-157 center on immunogenicity.

What the Research Shows

Evidence from regulatory records indicates that as of March 2026, many commonly discussed peptides remain non-FDA-approved for their popularized indications. BPC-157, TB-500, GHK-Cu, and GHRP-2 are classified as Category 2 substances under Section 503A, citing significant safety risks such as immunogenicity and a lack of human exposure data. Several substances, including AOD-9604, Ipamorelin, Selank, and CJC-1295, had their nominations withdrawn or were removed from consideration in September 2024.

In human clinical trials, Semaglutide demonstrated a 14.9% weight loss in the STEP 1 trial and a 20% reduction in Major Adverse Cardiovascular Events (MACE) in the SELECT trial. Tirzepatide showed superior results in the SURMOUNT-5 trial compared to semaglutide, with the SURMOUNT-1 trial recording 22.5% weight loss. Conversely, Thymosin Alpha-1 failed to show a mortality reduction in a Phase III sepsis trial (PMID: 39814420), although it remains approved as Zadaxin in over 35 countries outside the U.S.

Post-marketing safety data from FAERS for Semaglutide shows strong signal strength for gastrointestinal events, including nausea, vomiting, and delayed gastric emptying. More serious signals include acute pancreatitis (moderate signal) and intestinal obstruction/ileus, which was added to the label post-marketing. Emerging concerns involve Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which is under EMA review as of January 2025, and pulmonary aspiration risk during general anesthesia.

Mechanism

The provided data does not contain specific biochemical mechanism-of-action descriptions for the referenced peptides beyond regulatory notes. Regulatory documentation for BPC-157, TB-500, and GHK-Cu highlights "immunogenicity concerns" as a primary safety consideration. For CJC-1295, the FDA notes safety issues including increased heart rate. For Semaglutide, the clinical data notes that delayed gastric emptying may impact the absorption of oral medications.

Limitations of the Evidence

The primary limitation for peptides like BPC-157 and TB-500 is the total absence of human exposure data in the provided records. For AOD-9604, Ipamorelin, and Selank, regulatory nominations were withdrawn, resulting in a lack of recent advisory review data. While Semaglutide has robust Phase III data, safety signals such as suicidal ideation remain under evaluation; current data does not support a higher risk compared to background rates. The NAION signal for semaglutide is based on 96 cases through December 2024 and requires further formal review.

Clinical Takeaway

Physicians should note that most listed peptides (BPC-157, TB-500, CJC-1295, etc.) are currently ineligible for routine compounding due to FDA Category 2 status and safety concerns regarding immunogenicity. While GLP-1 receptor agonists like Semaglutide and Tirzepatide have demonstrated significant efficacy in Phase III trials, clinical management must account for emerging post-marketing signals related to gastrointestinal obstruction and perioperative pulmonary aspiration risk.

Sources

1. FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2; March 2026).
2. FAERS Safety Signal Records (Semaglutide 2023-2025).
3. Clinical Trial Records (NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267).

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.